Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, May 2001, p. 1407-1416, Vol. 45, No. 5
Department of Microbiology, Colorado State
University, Fort Collins, Colorado 805231;
College of Pharmacy, University of Illinois at Chicago,
Chicago, Illinois 606122; and Department
of Biology, Washington University, St. Louis, Missouri
631303
Received 14 August 2000/Returned for modification 3 October
2000/Accepted 12 February 2001
An L-rhamnosyl residue plays an essential structural
role in the cell wall of Mycobacterium tuberculosis.
Therefore, the four enzymes (RmlA to RmlD) that form dTDP-rhamnose from
dTTP and glucose-1-phosphate are important targets for the development
of new tuberculosis therapeutics. M. tuberculosis genes
encoding RmlA, RmlC, and RmlD have been identified and expressed in
Escherichia coli. It is shown here that genes for only
one isotype each of RmlA to RmlD are present in the M.
tuberculosis genome. The gene for RmlB is Rv3464. Rv3264c was
shown to encode ManB, not a second isotype of RmlA. Using recombinant
RmlB, -C, and -D enzymes, a microtiter plate assay was developed to
screen for inhibitors of the formation of dTDP-rhamnose. The three
enzymes were incubated with dTDP-glucose and NADPH to form
dTDP-rhamnose and NADP+ with a concomitant decrease in
optical density at 340 nm (OD340). Inhibitor candidates
were monitored for their ability to lower the rate of OD340
change. To test the robustness and practicality of the assay, a
chemical library of 8,000 compounds was screened. Eleven inhibitors
active at 10 µM were identified; four of these showed activities
against whole M. tuberculosis cells, with MICs from 128 to 16 µg/ml. A rhodanine structural motif was present in three of the
enzyme inhibitors, and two of these showed activity against whole
M. tuberculosis cells. The enzyme assay was used to
screen 60 Peruvian plant extracts known to inhibit the growth of
M. tuberculosis in culture; two extracts were active
inhibitors in the enzyme assay at concentrations of less than 2 µg/ml.
The necessity for new drugs against
Mycobacterium tuberculosis due to increasing resistance to
the present chemotherapeutic agents is well documented (6, 12,
21, 33, 41, 44). An attractive target for such new agents is the
mycobacterial cell wall (2, 3, 29), since the wall is
necessary for viability and several known drugs such as isoniazid
(52) and ethambutol (11, 49) inhibit cell
wall synthesis. The mycobacterial cell wall core consists of three
interconnected macromolecules (Fig.
1). The outermost, the mycolic acids, are
70- to 90-carbon-containing, branched fatty acids which form an outer
lipid layer in some ways similar to the classical outer membrane of
gram-negative bacteria (5). The mycolic acids are
esterified to the middle component, arabinogalactan (AG), a polymer
composed primarily of D-galactofuranosyl and
D-arabinofuranosyl residues. AG is connected via
a linker disaccharide,
0066-4804/01/$04.00+0 DOI: 10.1128/AAC.45.5.1407-1416.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Drug Targeting Mycobacterium
tuberculosis Cell Wall Synthesis: Genetics of dTDP-Rhamnose
Synthetic Enzymes and Development of a Microtiter Plate-Based
Screen for Inhibitors of Conversion of dTDP-Glucose to
dTDP-Rhamnose
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
-L-rhamnosyl-(1
3)-
-D-N-acetyl-glucosaminosyl-1-phosphate, to the 6 position of a muramic acid residue in the peptidoglycan. The
peptidoglycan is the innermost of the three cell wall core macromolecules.

View larger version (26K):
[in a new window]
FIG. 1.
Structure of the mycobacterial cell wall, drawn to
emphasize the role of the essential rhamnosyl residue. Also shown is
the formation of dTDP-Rha by the Rml enzymes and its use by rhamnosyl
transferase (WbbL). Not depicted is the fact that the rhamnosyl residue
is donated to the 3 position of the GlcNAc residue in the context of a
carrier lipid. The newly synthesized AG molecule is ultimately
transferred from the carrier lipid to peptidoglycan and mycolylated
(31).
This structural arrangement shows why AG is necessary for mycobacterial
viability, as it tethers the lipid layer to the peptidoglycan layer.
Moreover, a rhamnosyl residue, a sugar not found in humans, plays a
crucial structural role in the attachment of AG to peptidoglycan (Fig.
1). (L-Rhamnosyl residues are found in other
bacteria as components of O antigens or extracellular polysaccharides
but not as an essential cell wall component.)
L-Rhamnosyl residues are synthesized in nature
by a single pathway requiring four enzymes (RmlA to RmlD) and beginning
with TTP and
-D-glucose-1-phosphate (13, 19, 32,
36), as shown in Fig. 1. There is no salvage pathway for the
formation of dTDP-L-rhamnose (dTDP-Rha) as with GDP-L-fucose (38, 39), and when
L-rhamnose is utilized by bacteria as a carbon
source, it is isomerized and broken down into smaller metabolites
(26). Thus, the only way for M. tuberculosis to
form the cell wall rhamnosyl residue is as shown in Fig. 1. In another
study (J. A. Mills, K. Motichka, M. Jucker, H. P. Wu, B. C. Uhlic, R. J. Stern, M. S. Scherman, V. Vissa, W. Yan, M. Kundu, M. Kundu, and M. R. McNeil, unpublished data), it has been
shown that the rhamnosyl transferase (encoded by the gene
wbbL) that utilizes dTDP-Rha as a substrate to put the
rhamnosyl residue into cell wall AG is essential for bacterial growth.
Although the rhamnosyl transferase is a good drug target in itself,
there are many advantages in targeting the four enzymes required to
make its required substrate, dTDP-Rha. These include the facts that the
enzymes are soluble (22, 28, 46), that crystal structures
of these enzymes from bacteria are forthcoming (1,
15-17), and that for one of these enzymes, RmlB, detailed mechanistic studies have been performed (18, 34, 42, 45).
Although the completion of the entire genome sequence of M. tuberculosis (8) greatly aids in the identification of the enzymes involved in dTDP-L-rhamnose synthesis, unambiguous identification from just the sequence data is problematical. In addition, it is important to determine whether additional genes encoding isoenzymes for any of the key conversions exist, because inhibition of multiple enzymes catalyzing the same reaction might be difficult. Here, we report experiments to determine which of the genes encoding proteins with homology to RmlA to RmlD actually encode dTDP-Rha formation enzymes. Following this, a microtiter plate assay to identify inhibitors of the conversion of dTDP-glucose to dTDP-rhamnose by M. tuberculosis RmlB, -C, and -D was developed. The assay was used to screen both pure compounds and crude plant extracts.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Preparation of plasmids to express M. tuberculosis genes. Rv3264c, Rv3464, Rv3784, and Rv3468c were cloned into pET29b (Novagen, Madison, Wis.). PCR was conducted using the following primers (coding sequence to the right of the hyphen): Rv3264c, 5'GGAATTCCAT-ATGGCAACTCACCAAGTCGAT3' (sense) and 5'CCGCTCGAG-TCAAACGTCGGACGAGTAACGGA3' (antisense); Rv3464, 5'TTACAT-ATGCGGTTGCTAGTCACC3' (sense) and 5'TTACTCGAG-TCATTGACCGCGTTCTTGAT3' (antisense); Rv3784, 5'CGTAGGCATTA-ATGGAAATACTTGTCACCGG3' (sense) and 5'CCGCTCGAG-TTAGAGAACGCTGGAACCGCTA3' (antisense); and Rv3468c, 5'GCGTAGGCATTA-ATGGTGGGAACACATGCAGCCACC3' (sense) and 5'ATTCCGCTCGAG-TCAGGGCCTGGCCGGAGCAAACA3' (antisense). The PCR products were ultimately cloned into pET29b using the NdeI and XhoI sites present in pET29b (the PCR products of Rv3784 and Rv3468c were cleaved with AseI, which makes an overhang that can go into an NdeI site). Rv3464 was also cloned with an N-terminal His tag using 5'TTACAT-ATGCGGTTGCTAGTC3' (sense) and 5'TTACTCGAG-TCATTGACCGCGTTCTTG3' (antisense) using the NdeI and XhoI sites to clone into pET16b (Novagen).
Escherichia coli strains.
E. coli
DH5
(Life Technologies, Inc., Grand Island, N.Y.) was used for
cloning purposes. For expression, potential rmlB-bearing plasmids were electroporated into E. coli BL21(DE3)
(Novagen); the potential rmlA- or manB-bearing
plasmid (Rv3264c) was electroporated into E. coli
s
874(DE3) (22, 48).
Assay for
-D-glucose-1-phosphate
thymidylyltransferase (RmlA) and
-D-manose-1-phosphate
guanylyltransferase (ManB) activities.
To prepare the enzyme
extract, E. coli s
874(DE3) containing open reading frame
(ORF) Rv3264c cloned into pET29b (and, separately, an empty pET29b
control) was grown to an optical density (OD) of 0.6 to 0.7 with
agitation at 37°C. The culture was induced (at 37°C) with
isopropyl-
-D-thiogalactopyranoside (IPTG) at 1 mM for 3 h and harvested by centrifugation. The enzyme assay
mixture (total volume, 50 µl) contained ~25 pmol of
TDP-[14C]Glc (11,700 cpm), ~22 pmol of
GDP-[14C]Man (9,700 cpm), 50 nmol of
PPi (when present), 500 nmol of MgCl2, and 34 µg of E. coli soluble
protein (20,000 × g supernatant after sonication) in
50 mM HEPES buffer at pH 7.6. The E. coli cells from which
the soluble protein was prepared carried either pET29b (control) or
pET29b with a Rv3264c insert. The reaction mixture was incubated at
room temperature for 5 min and then boiled for 5 min followed by the
addition of dTDP-Rha (9,070 cpm) as an internal standard. Denatured
protein was removed by centrifuging at 14,000 × g for
5 to 10 min. The supernatant was analyzed by high-pressure liquid
chromatography (HPLC) using a PA-100 (Dionex, Sunnyvale, Calif.)
ion-exchange column with a gradient of 75 to 500 mM
KH2PO4 over a 30-min period
at a flow rate of 1 ml/min. Radioactive sugar nucleotides were detected
using a Beta-Ram (INUS, Tampa, Fla.) HPLC radio detector upon elution.
Assay for dTDP-glucose dehydratase (RmlB) activity. The assay for dTDP-glucose dehydratase (RmlB) activity was performed as previously described (53) by monitoring the appearance of a degradation compound(s) produced from the enzyme product, dTDP-6-deoxy-D-xylo-4-hexulose, in the presence of base. The E. coli cells with various plasmids were grown to an OD of 0.6 to 0.7 with agitation at 37°C. The cultures were cooled to room temperature (around 25°C) for 30 to 60 min, induced with IPTG at 1 mM for 3 to 5 h, and harvested by centrifugation. The cells were then broken by sonication, and 8 µg of soluble protein (20,000 × g supernatant) was added to 100 nmol of dTDP-Glc in a total of 200 µl of 50 mM HEPES (pH 7.6) containing 1 mM NAD+ (addition of NAD+ was necessary for the M. tuberculosis RmlB to retain enzymatic activity). After a 1-h incubation at 37°C, 1 ml of 0.1 M NaOH was added, the tube was incubated for 20 more minutes at 37°C, and the absorbance was read at 318 nm.
Purification of RmlB. E. coli BL21(DE3)(pET29b-Rv3464) cells were grown to an OD of 0.7 to 0.8 with agitation at 37°C. The culture was cooled to room temperature (around 25°C) for 30 to 60 min, induced with IPTG at 0.2 mM for 3 to 5 h, and harvested by centrifugation. Cells were broken using a French press in 50 mM Tris (pH 7.6) buffer containing 1 mM dithiothreitol, 1 µM pepstatin A, 1 µM leupeptin, and 0.1 mM phenylmethylsulfonyl fluoride. The soluble fraction (20,000 × g supernatant) was dialyzed into 25 mM Tris (pH 8.0) containing 50 mM NaCl at 4°C and applied to a DEAE Sephadex Fast Flow column (10-ml bed volume, 2-cm diameter) equilibrated in the same buffer. The column was eluted with 30 ml each of 100, 200, 300, and 500 mM NaCl in the Tris buffer; RmlB was found in the 200 mM fraction (as visualized by sodium dodecyl sulfate-polyacrylamide gel electrophoresis or by enzyme assay). The RmlB fraction was then dialyzed into 25 mM Tris (pH 8) containing 100 mM NaCl and concentrated to around 4 ml. This fraction was injected on HPLC using a Poros Pmax HQ/M (4.6 by 100 mm; Applied Biosystems-PerSeptive, Framingham, Mass.) ion-exchange column equilibrated with 25 mM Tris (pH 8) containing 100 mM NaCl. The flow rate was 5.1 ml/min. After a 2-min wash with 25 mM Tris (pH 8) containing 100 mM NaCl, a linear gradient to 400 mM Tris (pH 8) containing 500 mM NaCl over 10 min was run. Following a 4-min wash with the second buffer, the column was further washed with 25 mM Tris containing 1 M NaCl. Fractions (0.5 min/2.5 ml) were collected, and RmlB was located by sodium dodecyl sulfate-polyacrylamide gel electrophoresis or enzyme assay. The fractions containing the RmlB were dialyzed into 25 mM Tris (pH 8.0), concentrated to approximately 0.2 mg/ml by ultrafiltration, made 20% with respect to glycerol, and stored at 4°C.
Microtiter plate assay for production of dTDP-Rha from dTDP-glucose. The assay for production of dTDP-Rha was performed in standard, clear, spherical-bottom polystyrene microtiter plates in a volume of 100 µl. Typically, 2 µl containing 1 nmol (for pure compounds) and 5 µg (for plant extracts) of each inhibitor in dimethylsulfoxide (DMSO) were added, including a control inhibitor of 300 nmol of dTDP and a control of DMSO only. A cocktail (75 µl) of HEPES buffer (50 mM, pH 7.6, with 1 mM MgCl2 and 10% glycerol) containing 0.5 nmol of NAD+, 20 nmol of NADPH (prepared fresh daily), 1 µg of RmlB, 1 µg of RmlC, and 0.4 µg of RmlD was added to each well. (These enzyme amounts were found empirically to be in the range where the decrease of any of the three enzymes resulted in a decrease in overall activity.) The reactions were started by adding 20 nmol of dTDP-Glc in 25 µl of the HEPES buffer to each well, and the plate was incubated at 30°C. At different time points, samples were examined on an enzyme-linked immunosorbent assay plate reader, typically at 0, 10, 20, 30, 60, 90, and 120 min at 340 nm, and the data were analyzed by comparing the slopes of the potential inhibitors with the slopes of the controls using the computer program Excel. To assay RmlC, a 1-h preincubation using the above cocktail, modified to contain 2 µg of RmlB and no RmlC or RmlD, was performed to prepared dTDP-6-deoxy-D-xylo-4-hexulose in situ. Then, 0.25 µg of RmlC and 4 µg of RmlD and NADPH were added, and the reaction was monitored as described above. To assay RmlD, dTDP-6-deoxy-D-xylo-4-hexulose in situ in the same fashion and then 10 µg of RmlC and 0.4 µg of RmlD were added and the reaction was monitored as described above.
Assays against M. tuberculosis in culture. Compounds were assayed against M. tuberculosis H37Rv in culture by the Alamar blue assay as described previously (9).
| |
RESULTS |
|---|
|
|
|---|
Genes encoding RmlA.
We have reported the cloning and
expression of an M. tuberculosis gene encoding RmlA
(28). This gene was designated Rv0334 and identified as
rmlA in the genome sequence paper (8).
However, the genome was found to contain another ORF, Rv3264c, encoding a protein with strong homology to RmlA (8). In addition,
this ORF was in an operon with wbbL and rmlD (see
discussion of rmlD below), strongly suggesting a second
rmlA gene, and Rv3264c was therefore designated
rmlA2 (8). However, the protein encoded by this
ORF also showed homology to ManB, the analogous enzyme in GDP-mannose
synthesis that forms GDP-mannose from
-D-mannose-1-phosphate and GTP
(
-D-mannose-1-phosphate guanylyltransferase).
To resolve this issue, ORF Rv3264c was cloned into pET29b and expressed
in E. coli s
874(DE3), a strain (48) which
was modified to contain DE3 in the chromosome (22) and
which does not express an E. coli version of either
manB (as shown in Fig. 2) or
rmlA (also shown in Fig. 2; also, the rml genes,
which are part of the rfb cluster, are known to be deleted
[35, 48]). Extracts from the bacterium transformed with
pET29b-Rv3264c and pET29b (vector-only control) were assayed for both
-D-glucose-1-phosphate thymidylyltransferase (RmlA) and
-D-mannose-1-phosphate
guanylyltransferase (ManB) activities in the reverse-direction reaction
by monitoring the PPi-dependent loss of dTDP-Glc
and/or GDP-Man as shown in Fig. 2. The result was that the enzyme
expressed from the Rv3264c gene was active only against GDP-Man (Fig.
2), demonstrating that Rv3264c encodes ManB. These results were
consistent with a recent report of the purification of ManB from
Mycobacterium smegmatis (37), where the
N-terminal sequence of the M. smegmatis protein
(37) shows 17 identical amino acids out of 20 compared with the N-terminal region of the protein product of
Rv3264c. Also supporting this assignment is the fact Rv3264c is the
only potential copy of manB in the genome (8)
and, since mannose is a component in many M. tuberculosis
glycoconjugates, manB must be present. Therefore, as no
other genes with homology to rmlA are found in the M. tuberculosis genome, we conclude that only a single isotype of
this enzyme is present in M. tuberculosis.
|
Genes encoding RmlB. Four ORFs encoding proteins with homology to RmlB are found in the M. tuberculosis genome (8). The protein product of Rv3464 (designated rmlB in the genome sequence) shows the highest homology to RmlB of other organisms, but three other genes encoding proteins with significant homology to RmlB are Rv3634c (designated rmlB2 in the genome sequence), Rv3784 (designated epiB in the genome sequence), and Rv3468c (designated rmlB3 in the genome sequence).
Rv3634c has an N-terminal sequence identical, except for one amino acid, to that of UDP-galactose epimerase (GalE) purified from M. smegmatis (51). We thus conclude that this ORF encodes GalE rather than RmlB. GalE and RmlB enzymes catalyze similar oxidation at C-4 of a glucosyl residue and in general show strong homology to each other. Rv3464 was cloned into pET29b and expressed in E. coli BL21(DE3), and the enzyme was partially purified. The band of the putative RmlB protein was blotted to nitrocellulose and trypsinized, and the resulting peptides was analyzed by liquid chromatography-mass spectrometry, which confirmed the identity of the expressed polypeptide. The two remaining candidates, Rv3784 and Rv3468c, were also cloned into pET29b and expressed in soluble form in E. coli BL21(DE3). Extracts containing the expressed protein were then assayed for dTDP-glucose dehydratase (RmlB) activity. Activity (OD at 318 nm [OD318] = 0.425) was readily observed for the strain expressing Rv3464, but no activity was seen for the strains expressing Rv3784 (OD318 = 0.046) or Rv3468c (OD318 = 0.068) or a control strain containing only the empty pET29b vector (OD318 = 0.074). These results are consistent with only one isotype of RmlB, the one that shows a very high homology with RmlB from other organisms, although the limitations of drawing conclusions from the lack of enzymatic activity are recognized.Genes encoding RmlC and for RmlD. The M. tuberculosis genome sequence (8) shows only a single ORF encoding a protein with homology for RmlC (Rv3465) and also only a single ORF encoding a protein with homology for RmlD (Rv3266c). Both Rv3465 (46) and Rv3266c (22) have previously been expressed, and these genes do express the dTDP-6-deoxy-D-xylo-4-hexulose epimerase (RmlC) and dTDP-6-deoxy-L-lyxo-4-hexulose reductase (RmlD) enzymes, respectively. Thus, only single polypeptides with sequences corresponding to RmlC and RmlD are present in the M. tuberculosis genome.
Development of a microtiter-based assay for RmlB, -C, and -D.
The fact that RmlD converts
dTDP-6-deoxy-L-lyxo-4-hexulose to dTDP-Rha
with the concomitant oxidation of NADPH to
NADP+ makes possible a facile microtiter plate
assay. Thus, a mixture of RmlB (this study), RmlC (46),
and RmlD (22) was incubated with dTDP-Glc (0.2 mM) and
NADPH (0.2 mM) in microtiter plates at 37°C, and the
OD340 was monitored. Controls with no dTDP-Glc and with an inhibitor, dTDP, were also performed. The
OD340 drops in a linear fashion in the early part
of the time course (Fig. 3B [control
reaction]). It was found necessary to purify all enzymes to avoid a
non-dTDP-Glc-dependent oxidation of NADPH. NAD+
was also included in the reaction mixtures, since it was found that
after purification of RmlB it was necessary to keep the enzyme active.
It was also found that individual proteins had to be sufficiently pure
not to reduce NAD+ to NADH (which absorbs at
OD340), presumably via oxidation of glycerol
present to help with the storage of the enzymes.
|
Use of the microtiter plate-based assay to search for
inhibitors.
The microtiter plate assay can be used to screen for
inhibitors among drug candidates obtained in microtiter plate
format. The slope of the oxidation of NADPH of wells with compounds is compared to that of the no-compound control and converted to percent inhibition by the formula (1
mwith
inhibitor/mwithout
inhibitor) × 100. Thus, a perfect inhibitor
would have a slope of 0 and 100% inhibition; a compound that showed no
inhibition would have the same slope as the no-compound control and
have an inhibition of 0%. The compound dTDP is run as a positive
inhibitor control with typically 80% inhibition at 3 mM.
|
|
| |
DISCUSSION |
|---|
|
|
|---|
Identification of dTDP-Rha-synthesizing genes. Only one copy each of rmlC and rmlD is present in the M. tuberculosis genome (8), and we have shown previously that the genes do in fact encode the expected enzymes (22, 46). The situation for rmlA is now also seen to be unambiguous, as only two candidate genes are present and we have clearly shown the function of Rv0334 to be encoding RmlA (26) and that of Rv3264c to be encoding ManB (this study). The situation is not as clear-cut for the rmlB gene. Rv3464 clearly encodes RmlB, as active enzyme can be expressed from it. Rv3634c encodes a protein with homology to RmlB, but the fact that its N-terminal sequence is nearly identical to that of UDP-galactose epimerase (GalE) from M. smegmatis (51) indicates that this gene encodes the GalE protein. Two other possible candidates, Rv3784 and Rv3468c, have been identified in the genome sequence (8); our data suggest that these genes do not encode RmlB, because they can be expressed as soluble proteins that do not show dTDP-glucose dehydratase (RmlB) activity. However, we cannot rule out the possibility that the soluble proteins were merely inactive RmlB. Therefore, it is most likely that only one isoform of RmlB is present in M. tuberculosis, but this has not yet been established unequivocally.
Genome organization of dTDP-Rha-synthesizing genes. In most other organisms, such as E. coli, rmlABCD are on a single operon, often in the order B, D, A, C (24, 40, 43, 47). However, from the results above and the genome sequence (8), it is clear that in M. tuberculosis the four genes responsible for dTDP-Rha formation are in three different loci. Thus, rmlA (Rv0334) is separate from all the other genes involved in rhamnose metabolism and appears to be the fourth gene in an operon where the functions of the proteins encoded by the other three genes are not known. The genes rmlB and rmlC (Rv3464 and Rv3465) are the second and third genes in a complex operon with perhaps five genes, where the last two genes are part of an insertion sequence (25) and the first gene encodes a protein with an unknown function. Finally, rmlD (Rv3266c) is the first gene of a three-gene operon. In this case the second gene is wbbL, encoding rhamnosyl transferase, and the third is manB (designated rmlA-2 in the genome sequence [8]), whose function is revealed in this report. There is some logic in the coordination of expression of manB with the rhamnose genes, as manB is needed for all mannosyl glycolipids (4) and polysaccharides (7), which, like rhamnosyl residues, are an important part of the mycobacterium envelope (30). The finding, however, that the rml genes are so scattered throughout the genome is surprising.
Comparison of rhamnosyl formation enzyme genes in M. tuberculosis and Mycobacterium leprae. It is of interest to compare the rhamnosyl-forming enzymes in M. tuberculosis and M. leprae. The sequencing of the M. leprae genome is just being completed. The genome of M. leprae is smaller than that of M. tuberculosis, many potential ORFs are degraded, and half of the DNA is noncoding (20). Since the cell wall AGs of M. leprae and M. tuberculosis are nearly identical (10), it stands to reason that the genes involving rhamnosyl formation enzymes should be amongst the intact genes found in the M. leprae genome. BLAST searches of the nearly completed M. leprae genome confirm that this is indeed true; rmlABCD and wbbL are all five intact in M. leprae, and, interestingly, the grouping of the genes in the various operons is the same in both mycobacteria, although the arrangement and orientation of the operons themselves along the genome are different. This result is consistent with the essential function of rhamnosyl residues in mycobacteria.
Targeting dTDP-Rha formation in M.
tuberculosis.
Targeting dTDP-Rha formation in M. tuberculosis has much to recommend it. Four enzymes are involved,
and all of them catalyze reactions that are not found in humans
(although the formation of UDP-glucose from
-D-glucose-1-phosphate and UTP is quite
homologous to the formation of dTDP-Glc catalyzed by RmlA). The enzymes
are soluble and can be readily prepared in large amounts. X-ray
structural analysis is becoming available for the Salmonella
homologs of these enzymes (1, 15-17), with efforts
proceeding on the M. tuberculosis versions. Mechanisms of
action and kinetic parameters are becoming known (18, 19, 34, 42,
45). The rhamnosyl transferase, WbbL, which uses dTDP-Rha as its
substrate to insert the rhamnosyl residue in the cell wall, is
essential for growth, as shown by the fact that an M. smegmatis TS mutant of WbbL differing in a single amino acid
(GenBank accession numbers AAF04375 and AAF04376) do not grow at the
nonpermissive temperature (Mills et al., unpublished). There is no
known way in nature to form dTDP-Rha other than by these enzymes.
Finally, three of the enzymes (RmlB, -C, and -D) are readily assayed
together by monitoring the oxidation of NADPH, and this assay is
readily adaptable to microtiter plates (Fig. 3) and can be used to
identify inhibitors (Table 1 and Fig. 3 and 4).
Use of the microtiter plate assay. The microtiter plate assay for RmlB, RmlC, and RmlD described above has the advantage of screening for inhibitors of three key enzymes at the same time. In practice we have found that preparing the three enzymes from E. coli in sufficient purity for the assay is straightforward but does require some care in adequately washing nickel columns when they are used in the purification. Although the experiments reported herein were done using a non-His-tagged version of RmlB, for convenience His-tagged RmlB from M. tuberculosis can readily be cloned (see Materials and Methods) and purified by standard methods after expression in E. coli and used successfully in the assay (data not shown). In identifying active inhibitors we selected compounds that inhibited the formation of dTDP-Rha more than 60%. Compounds showing activity were then retested, and generally the percent inhibition was reproducible to roughly ±20%, allowing a clear separation of active and inactive inhibitors under the conditions of the assay.
The most important finding of the present investigation is the fact that the Rml enzyme assay is sufficiently robust to uncover potential enzyme inhibitors as a starting place for continued analysis. Most compounds selected by the screen were active against more than a single enzyme. Given the structural similarities of the substrates for all three enzymes, this is perhaps not surprising. It was interesting that three of the eleven compounds (5372, 6429, and 6432) had a rhodanine core structure and a fourth (2943) had a core structure very similar to that of rhodanine. There were at least six other compounds in the Nanosyn library that had rhodanine rings but were not active in the enzyme assay, suggesting some very preliminary structure-activity relationships. It was also encouraging that four of the eleven active compounds identified in this preliminary study inhibited the growth of M. tuberculosis in culture (albeit usually at high concentrations [Table 1]). Clearly, more work must be done to show that such compounds actually affect growth of M. tuberculosis via inhibition of the rhamnosyl enzymes. Also, much work remains to identify further classes of active compounds and to determine which molecules have appropriate properties for further development. On a somewhat different track, compounds identified as enzyme inhibitors are candidates for cocrystallization with the enzymes they inhibit to reveal useful binding structures, regardless of their other properties. The assay described here should be suitable for screening very large numbers of compounds. Although it was performed here in a 96-well format, there is no reason not to use 384-well plates or even plates containing higher number of wells, as only the OD340 needs to be monitored. The most expensive reagent is the dTDP-glucose, and the amounts of it can be decreased if a smaller overall change in OD can be tolerated (as reported here, the utilization of all the dTDP-glucose will result an OD drop of about 0.3 units). Small well sizes will also allow the use of less dTDP-glucose and will require less enzyme as well.| |
ACKNOWLEDGMENTS |
|---|
This work was supported by funds provided through the Public Health Service (NIAID, NIH; AI-33706) and through the National Cooperative Drug Discovery Group program (NIAID, NIH; U19 AI 40972 and P01 AI 46393).
We gratefully thank John Belisle and Barbara Covert for liquid chromatography-mass spectrometry sequencing of RmlB and Amber Safford, Angela Richards, and Mark Pilgard for skilled technical assistance. We also thank Sandeep Shankar for valuable discussions and advice.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Microbiology, Colorado State University, Fort Collins, CO 80523. Phone: (970) 491-1784. Fax: (970) 491-1815. E-mail: mmcneil{at}cvmbs.colostate.edu.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Allard, S. T. M., M.-F. Giraud, C. Whitfield, P. Messner, and J. H. Naismith. 2000. The purification, crystallization and structural elucidation of dTDP-D-glucose 4,6-dehydratase (RmlB), the second enzyme of the dTDP-L- rhamnose synthesis pathway from Salmonella enterica serovar typhimurium. Acta Crystallogr. D 56(Pt. 2):222-225[CrossRef][Medline]. |
| 2. | Barry, C. E., III. 1997. New horizons in the treatment of tuberculosis. Biochem. Pharmacol. 54:1165-1172[CrossRef][Medline]. |
| 3. | Besra, G. S., and P. J. Brennan. 1997. The mycobacterial cell envelope: a target for novel drugs against tuberculosis. J. Pharm. Pharmacol. 49(Suppl. 1):25-30. |
| 4. |
Brennan, P. J., and C. E. Ballou.
1968.
Biosynthesis of mannophosphoinositides by Mycobacterium phlei.
J. Biol. Chem.
243:2975-2984 |
| 5. | Brennan, P. J., and H. Nikaido. 1995. The envelope of mycobacteria. Annu. Rev. Biochem. 64:29-63[CrossRef][Medline]. |
| 6. | Chase, M. 1999. New, virulent forms of tuberculosis spur concerns world-wide. The Wall Street Journal 1999(Dec. 17):B1. |
| 7. |
Chatterjee, D., and K. H. Khoo.
1998.
Mycobacterial lipoarabinomannan: an extraordinary lipoheteroglycan with profound physiological effects.
Glycobiology
8:113-120 |
| 8. | Cole, S. T., R. Brosch, J. Parkhill, T. Garnier, C. Churcher, D. Harris, S. V. Gordon, K. Eiglmeier, S. Gas, C. E. Barry, F. Tekaia, K. Badcock, D. Basham, D. Brown, T. Chillingworth, R. Connor, R. Davies, K. Devlin, T. Feltwell, S. Gentles, N. Hamlin, S. Holroyd, T. Hornby, K. Jagels, A. Krogh, J. McLean, S. Moule, L. Murphy, K. Oliver, J. Osborne, M. A. Quail, M. A. Rajandream, J. Rogers, S. Rutter, K. Seeger, J. Skelton, R. Squares, S. Squares, J. E. Sulston, K. Taylor, S. Whitehead, and B. G. Barrell. 1998. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393:537-544[CrossRef][Medline]. |
| 9. | Collins, L. A., and S. G. Franzblau. 1997. Microplate Alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. Antibiot. Chemother. 41:1004-1009. |
| 10. | Daffe, M., M. McNeil, and P. J. Brennan. 1993. Major structural features of the cell wall arabinogalactans of Mycobacterium, Rhodococcus, and Nocardia spp. Carbohydr. Res. 249:383-398[CrossRef][Medline]. |
| 11. | Deng, L., K. Mikusova, K. G. Robuck, M. Scherman, P. J. Brennan, and M. McNeil. 1995. Recognition of multiple effects of ethambutol on the metabolism of the mycobacterial cell envelope. Antimicrob. Agents Chemother. 39:694-701[Abstract]. |
| 12. | Enarson, D. A., and J. F. Murray. 1996. Global epidemiology of tuberculosis, p. 57-75. In W. N. Rom, and S. Garay (ed.), Tuberculosis. Little, Brown and Company, Boston, Mass. |
| 13. |
Gabriel, O., and G. Ashwell.
1965.
Biological mechanisms involved in the formation of deoxysugars. I. Preparation of thymidine diphosphate glucose labeled specifically in carbon 3.
J. Biol. Chem.
240:4123-4127 |
| 14. | Ghose, A. K., V. N. Viswanadhan, and J. J. Wendoloski. 1999. A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. J. Comb. Chem. 1:55-68[CrossRef][Medline]. |
| 15. | Giraud, M.-F., F. M. Gordon, C. Whitfield, P. Messner, S. A. McMahon, and J. H. Naismith. 1999. Purification, crystallization and preliminary structural studies of dTDP-6-deoxy-D-xylo-4-hexulose 3,5-epimerase (RmlC), the third enzyme of the dTDP-L-rhamnose synthesis pathway, from Salmonella enterica serovar typhimurium. Acta Crystallogr. D 55:706-708[CrossRef][Medline]. |
| 16. | Giraud, M.-F., G. A. Leonard, R. A. Field, C. Berlind, and J. H. Naismith. 2000. RmlC, the third enzyme of dTDP-L-rhamnose pathway, is a new class of epimerase. Nat. Struct. Biol. 7:398-402[CrossRef][Medline]. |
| 17. | Giraud, M.-F., H. J. McMiken, G. A. Leonard, P. Messner, C. Whitfield, and J. H. Naismith. 1999. Overexpression, purification, crystallization and preliminary structural study of dTDP-6-deoxy-L-lyxo-4-hexulose reductase (RmlD), the fourth enzyme of the dTDP-L-rhamnose synthesis pathway, from Salmonella enterica serovar typhimurium. Acta Crystallogr. D 55(Pt 12):2043-2046[CrossRef][Medline]. |
| 18. | Glaser, L., and L. Ward. 1970. Intramolecular hydrogen transfer catalyzed by UDP-D-glucose 4'- epimerase from Escherichia coli. Biochim. Biophys. Acta 198:613-615[Medline]. |
| 19. |
Graninger, M.,
B. Nidetzky,
D. E. Heinrichs,
C. Whitfield, and P. Messner.
1999.
Characterization of dTDP-4-dehydrorhamnose 3,5-epimerase and dTDP-4-dehydrorhamnose reductase, required for dTDP-L-rhamnose biosynthesis in Salmonella enterica serovar typhimurium LT2.
J. Biol. Chem.
274:25069-25077 |
| 20. |
Hagmann, M.
2000.
Intimate portraits of bacterial nemeses.
Science
288:800-801 |
| 21. | Harkin, T. J., and H. W. Harris. 1996. Treatment of multidrug-resistant tuberculosis, p. 843-850. In W. N. Rom, and S. Garay (ed.), Tuberculosis. Little, Brown and Company, Boston, Mass. |
| 22. | Hoang, T. T., Y. F. Ma, R. J. Stern, M. R. McNeil, and H. P. Schweizer. 1999. Construction and use of low-copy number T7 expression vectors for purification of problem proteins: purification of Mycobacterium tuberculosis RmlD and Pseudomonas aeruginosa LasI and RhlI proteins, and functional analysis of purified RhlI. Gene 237:361-371[CrossRef][Medline]. |
| 23. |
Kornfeld, S., and L. Glaser.
1961.
The enzymatic synthesis of thymidine-linked sugars. I. Thymidine diphosphate glucose.
J. Biol. Chem.
236:1791-1794 |
| 24. |
Lee, S. J.,
L. K. Romana, and P. R. Reeves.
1992.
Sequence and structural analysis of the rfb (O antigen) gene cluster from a group C1 Salmonella enterica strain.
J. Gen. Microbiol.
138:1843-1855 |
| 25. | Lee, T. Y., T. J. Lee, J. T. Belisle, P. J. Brennan, and S. K. Kim. 1997. A novel repeat sequence specific to Mycobacterium tuberculosis complex and its implications. Tubercle Lung Dis. 78:13-19[CrossRef][Medline]. |
| 26. | Lin, E. C. C. 1987. Dissimilatory pathways for sugars, polyols, and carboxylates, p. 244-284. In F. C. Neidhardt, et al. (ed.), Escherichia coli and Salmonella typhimurium: cellular and molecular biology. American Society for Microbiology, Washington, D.C. |
| 27. | Lipinski, C. A., F. Lombardo, B. W. Dominy, and P. J. Feeney. 1997. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Syst. 23:3-25[CrossRef]. |
| 28. |
Ma, Y.,
J. A. Mills,
J. T. Belisle,
V. Vissa,
M. Howell,
K. Bowlin,
M. S. Scherman, and M. McNeil.
1997.
Drug targeting rhamnose biosynthesis in mycobacteria: determination of the pathway for rhamnose biosynthesis in mycobacteria and cloning, sequencing, expressing and determining the genetic organization of the Mycobacterium tuberculosis gene encoding -D-glucose-1-phosphate thymidylyltransferase.
Microbiology
143:937-945 |
| 29. | McNeil, M. 1996. Target preclinical drug development for Mycobacterium avium complex: a biochemical approach, p. 263-283. In J. A. Korvick, and C. A. Benson (ed.), Mycobacterium avium-complex infection. Marcel Dekker, Inc, New York, N.Y. |
| 30. | McNeil, M., G. S. Besra, and P. J. Brennan. 1996. Chemistry of the mycobacterial cell wall, p. 171-186. In W. N. Rom, and S. M. Garay (ed.), Tuberculosis. Little, Brown and Company, Boston, Mass. |
| 31. | McNeil, M. R. 1999. Arabinogalactan in mycobacteria: structure, biosynthesis, and genetics, p. 207-223. In J. B. Goldberg (ed.), Genetics of bacterial polysaccharides. CRC Press, Boca Raton, Fla. |
| 32. |
Melo, A.,
W. H. Elliott, and L. Glaser.
1968.
The mechanism of 6-deoxyhexose synthesis. I. Intramolecular hydrogen transfer catalyzed by deoxythymidine diphosphate D-glucose oxidoreductase.
J. Biol. Chem.
243:1467-1474 |
| 33. | Moran, N. 1996. W. H. O. issues another gloomy tuberculosis report. Nat. Med. 2:377-377[CrossRef][Medline]. |
| 34. | Naundorf, A., and W. Klaffke. 1996. Substrate specificity of native dTDP-D-glucose-4,6-dehydratase: chemo-enzymatic syntheses of artificial and naturally occurring deoxy sugars. Carbohydr. Res. 285:141-150[Medline]. |
| 35. |
Neuhard, J., and E. Thomassen.
1976.
Altered deoxyribonucleotide pools in P2 eductants of Escherichia coli K-12 due to deletion of the dcd gene.
J. Bacteriol.
126:999-1001 |
| 36. | Nikaido, H., K. Nikaido, and A. M. C. Rapis. 1965. Biosynthesis of thymidine diphosphate L-rhamnose in Escherichia coli K-12. Biochem. Biophys. Acta 111:548-551[Medline]. |
| 37. | Ning, B., and A. D. Elbein. 1999. Purification and properties of mycobacterial GDP-mannose pyrophosphorylase. Arch. Biochem. Biophys. 362:339-345[CrossRef][Medline]. |
| 38. |
Park, S. H.,
I. Pastuszak,
R. Drake, and A. D. Elbein.
1998.
Purification to apparent homogeneity and properties of pig kidney L-fucose kinase.
J. Biol. Chem.
273:5685-5691 |
| 39. |
Pastuszak, I.,
C. Ketchum,
G. Hermanson,
E. J. Sjoberg,
R. Drake, and A. D. Elbein.
1998.
GDP-L-fucose pyrophosphorylase. Purification, cDNA cloning, and properties of the enzyme.
J. Biol. Chem.
273:30165-30174 |
| 40. |
Rajakumar, K.,
B. H. Jost,
C. Sasakawa,
N. Okada,
M. Yoshikawa, and B. Adler.
1994.
Nucleotide sequence of the rhamnose biosynthetic operon of Shigella flexneri 2a and role of lipopolysaccharide in virulence.
J. Bacteriol.
176:2362-2373 |
| 41. | Ramaswamy, S., and J. M. Musser. 1998. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber. Lung Dis. 79:3-29[CrossRef][Medline]. |
| 42. |
Ramaswamy, S. V.,
A. G. Amin,
S. Goksel,
C. E. Stager,
S.-J. Dou,
H. El Sahly,
S. L. Moghazeh,
B. N. Kreiswirth, and J. M. Musser.
2000.
Molecular genetic analysis of nucleotide polymorphisms associated with ethambutol resistance in human isolates of Mycobacterium tuberculosis.
Antimicrob. Agents Chemother.
44:326-336 |
| 43. | Reeves, P. R., M. Hobbs, M. A. Valvano, M. Skurnik, C. Whitfield, D. Coplin, N. Kido, J. Klena, D. Maskell, C. R. Raetz, and P. D. Rick. 1996. Bacterial polysaccharide synthesis and gene nomenclature. Trends Microbiol. 4:495-503[CrossRef][Medline]. |
| 44. | Rouhi, A. M. 1999. Tuberculosis: a tough adversary. Chem. Eng. News 77:52. |
| 45. | Russell, R. N., and H. W. Liu. 1991. Stereochemical and mechanistic studies of CDP-D-glucose oxidoreductase isolated from Yersinia pseudotuberculosis. J. Am. Chem. Soc. 113:7777-7778[CrossRef]. |
| 46. | Stern, R. J., T. Y. Lee, T. J. Lee, W. Yan, M. S. Scherman, V. D. Vissa, S. K. Kim, B. L. Wanner, and M. R. McNeil. 1999. Conversion of dTDP-4-keto-6-deoxyglucose to free dTDP-4-keto-rhamnose by the rmlC gene products of Escherichia coli and Mycobacterium tuberculosis. Microbiology 145:663-671[CrossRef][Medline]. |
| 47. |
Stevenson, G.,
K. Andrianopoulos,
M. Hobbs, and P. R. Reeves.
1996.
Organization of the Escherichia coli K-12 gene cluster responsible for production of the extracellular polysaccharide colanic acid.
J. Bacteriol.
178:4885-4893 |
| 48. |
Stevenson, G.,
B. Neal,
D. Liu,
M. Hobbs,
N. H. Packer,
M. Batley,
J. W. Redmond,
L. Lindquist, and P. R. Reeves.
1994.
Structure of the O antigen of Escherichia coli K-12 and the sequence of its rfb gene cluster.
J. Bacteriol.
176:4144-4156 |
| 49. |
Takayama, K., and J. O. Kilburn.
1989.
Inhibition of synthesis of arabinogalactan by ethambutol in Mycobacterium smegmatis.
Antimicrob. Agents Chemother.
33:1493-1499 |
| 50. | Timmermann, B. N., G. Wachter, S. Valcic, B. Hutchinson, C. Casler, J. Henzel, S. Ram, F. Currim, R. Manak, S. Franzblau, W. Maiese, D. Galanis, E. Suarez, R. Fortunato, E. Saavedra, R. Bye, R. Mata, and G. Montenegro. 2000. The Latin American ICBG: the first five years. Pharm. Biol. 37(Suppl.):35-54[CrossRef]. |
| 51. | Weston, A., R. J. Stern, R. E. Lee, P. M. Nassau, D. Monsey, S. L. Martin, M. S. Scherman, G. S. Besra, K. Duncan, and M. R. McNeil. 1997. Biosynthetic origin of mycobacterial cell wall galactofuranosyl residues. Tuber. Lung Dis. 78:123-131[CrossRef][Medline]. |
| 52. | Winder, F. G. 1982. Mode of action of the antimycobacterial agents and associated aspects of the molecular biology of the mycobacteria, p. 354-442. In C. Ratledge, and J. Standford (ed.), The biology of the mycobacteria, vol. 1. Academic Press, London, United Kingdom. |
| 53. |
Zarkowsky, H., and L. Glaser.
1969.
The mechanism of 6-deoxyhexose synthesis. III. Purification of deoxythymidine diphosphate-glucose oxidoreductase.
J. Biol. Chem.
244:4750-4756 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»